Hospital-acquired pneumonia medical therapy: Difference between revisions
Jump to navigation
Jump to search
Line 11: | Line 11: | ||
* [[Vancomycin]] | * [[Vancomycin]] | ||
* [[Linezolid]] | * [[Linezolid]] | ||
* [[Teicoplanin]] | |||
* In case no MRSA is isolated on culture these antibiotics should be discontinued. | * In case no MRSA is isolated on culture these antibiotics should be discontinued. | ||
===Side-effects of Linezolid=== | ===Side-effects of Linezolid=== | ||
* [[Thrombocytopenia]] | * [[Thrombocytopenia]] |
Revision as of 17:34, 11 September 2012
Hospital-acquired pneumonia Microchapters |
Differentiating Hospital-Acquired Pneumonia from other Diseases |
Diagnosis |
Treatment |
Case Studies |
Hospital-acquired pneumonia medical therapy On the Web |
American Roentgen Ray Society Images of Hospital-acquired pneumonia medical therapy |
Directions to Hospitals Treating Hospital-acquired pneumonia |
Risk calculators and risk factors for Hospital-acquired pneumonia medical therapy |
Editor(s)-in-Chief: C. Michael Gibson, M.S., M.D. [1] Phone:617-632-7753; Philip Marcus, M.D., M.P.H.[2]
Overview
Antimicrobial therapy
Patients prone to Methicillin-resistant staphylococcus aureus
- Critically ill patients
- History of recent antibiotic therapy
- Patient admitted in a hospital with increased incidence of MRSA.
Antibiotic choice for MRSA
- Vancomycin
- Linezolid
- Teicoplanin
- In case no MRSA is isolated on culture these antibiotics should be discontinued.
Side-effects of Linezolid
- Thrombocytopenia
- Gastrointestinal side-effects
- Renal dysfunction